Veradigm Past Earnings Performance
Past criteria checks 0/6
There is insufficient data on Veradigm's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Healthcare Services Industry Growth | 1.7% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
Recent updates
Veradigm (NASDAQ:MDRX) Is Doing The Right Things To Multiply Its Share Price
Feb 28
Veradigm (NASDAQ:MDRX) Might Have The Makings Of A Multi-Bagger
Nov 10Veradigm's (NASDAQ:MDRX) Returns On Capital Are Heading Higher
Mar 06Is It Too Late To Consider Buying Veradigm Inc. (NASDAQ:MDRX)?
Feb 13Veradigm Inc. (NASDAQ:MDRX) Shares Could Be 47% Below Their Intrinsic Value Estimate
Jan 22These 4 Measures Indicate That Veradigm (NASDAQ:MDRX) Is Using Debt Reasonably Well
Jan 04Returns Are Gaining Momentum At Allscripts Healthcare Solutions (NASDAQ:MDRX)
Dec 03Allscripts Healthcare reaffirms 2022 financial guidance; shares fall 2%
Sep 28Should You Think About Buying Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) Now?
Sep 17Investors Will Want Allscripts Healthcare Solutions' (NASDAQ:MDRX) Growth In ROCE To Persist
Aug 24We Think Allscripts Healthcare Solutions (NASDAQ:MDRX) Is Taking Some Risk With Its Debt
Jul 31Is Now An Opportune Moment To Examine Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX)?
Jun 15We Like These Underlying Return On Capital Trends At Allscripts Healthcare Solutions (NASDAQ:MDRX)
May 03These 4 Measures Indicate That Allscripts Healthcare Solutions (NASDAQ:MDRX) Is Using Debt Reasonably Well
Apr 12Allscripts Healthcare Solutions' (NASDAQ:MDRX) Robust Earnings Might Be Weaker Than You Think
Mar 04Allscripts Healthcare Solutions: Fundamentals Are Improving, But Consistency Needs To Be Established
Feb 27Revenue & Expenses BreakdownBeta
How Veradigm makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 1,529 | 116 | 360 | 201 |
| 30 Jun 22 | 1,522 | 125 | 354 | 198 |
| 31 Mar 22 | 1,512 | 148 | 323 | 196 |
| 31 Dec 21 | 1,503 | 134 | 314 | 194 |
| 30 Sep 21 | 806 | -14 | 181 | 117 |
| 30 Jun 21 | 1,027 | -48 | 248 | 142 |
| 31 Mar 21 | 1,255 | -96 | 329 | 167 |
| 31 Dec 20 | 1,503 | -133 | 390 | 206 |
| 30 Sep 20 | 1,428 | -143 | 390 | 196 |
| 30 Jun 20 | 1,507 | -134 | 398 | 213 |
| 31 Mar 20 | 1,582 | -263 | 393 | 231 |
| 31 Dec 19 | 1,633 | -238 | 401 | 245 |
| 30 Sep 19 | 1,763 | -197 | 405 | 268 |
| 30 Jun 19 | 1,751 | -203 | 412 | 257 |
| 31 Mar 19 | 1,748 | 34 | 430 | 268 |
| 31 Dec 18 | 1,618 | -39 | 431 | 259 |
| 30 Sep 18 | 1,516 | 70 | 407 | 248 |
| 30 Jun 18 | 1,533 | 54 | 416 | 246 |
| 31 Mar 18 | 1,518 | -187 | 405 | 218 |
| 31 Dec 17 | 1,498 | -183 | 401 | 202 |
| 30 Sep 17 | 1,714 | -210 | 451 | 195 |
| 30 Jun 17 | 1,657 | -191 | 433 | 189 |
| 31 Mar 17 | 1,618 | -48 | 415 | 190 |
| 31 Dec 16 | 1,386 | 31 | 335 | 179 |
| 30 Sep 16 | 1,470 | -2 | 380 | 186 |
| 30 Jun 16 | 1,432 | 3 | 362 | 189 |
| 31 Mar 16 | 1,397 | 10 | 347 | 185 |
| 31 Dec 15 | 1,386 | -2 | 339 | 185 |
| 30 Sep 15 | 1,382 | -21 | 320 | 180 |
| 30 Jun 15 | 1,373 | -41 | 339 | 179 |
| 31 Mar 15 | 1,372 | -56 | 345 | 187 |
| 31 Dec 14 | 1,378 | -66 | 359 | 193 |
| 30 Sep 14 | 1,388 | -85 | 380 | 198 |
| 30 Jun 14 | 1,373 | -108 | 384 | 199 |
| 31 Mar 14 | 1,366 | -113 | 392 | 197 |
| 31 Dec 13 | 1,373 | -104 | 395 | 196 |
| 30 Sep 13 | 1,373 | -108 | 383 | 199 |
| 30 Jun 13 | 1,404 | -49 | 369 | 190 |
Quality Earnings: Insufficient data to determine if MDRX has high quality earnings.
Growing Profit Margin: Insufficient data to determine if MDRX's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if MDRX's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare MDRX's past year earnings growth to its 5-year average.
Earnings vs Industry: Insufficient data to determine if MDRX's earnings growth over the past year exceeded the Healthcare Services industry average.
Return on Equity
High ROE: MDRX has a negative Return on Equity (0%), as it is currently unprofitable.